Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.
Careers. If you love the intellectual challenge of working in a fast-paced, results-driven organization, there is a home for you at CrownBio Theo Melas-Kyriazi Director. Theo Melas-Kyriazi joined Flagship Pioneering as an Executive Partner in April 2019. Prior to joining the firm, Theo served as chief financial officer of Levitronix Technologies, a worldwide leader in magnetically levitated bearingless motor technology.
The exosomes that Codiak is creating are unique in that they are engineered to have precise properties, incorporate various types of biologically active molecules, and can be directed to specific cell types and tissues. Founded in 2015 and based in Cambridge, Mass., Codiak has been a Goodwin client and key partner since inception. Jan 05, 2016 · Codiak BioSciences is a venture-backed start-up dedicated to harnessing the power of exosomes as both therapeutics and diagnostics in cancer and other diseases. Codiak is building a world-class team and has generated, acquired and licensed foundational intellectual property to enable the development of products that capitalize on the unique biology of exosomes. This is an initial public offering of shares of common stock by Codiak BioSciences, Inc. We are offering shares of our common stock. The initial public offering price is expected to be between $ and $ per share. Prior to this offering, there has been no public market for our common stock. Jul 01, 2019 · Citing market conditions, Codiak BioSciences (CDAK) has withdrawn its planned IPO. May 09, 2019 · Quick TakeCodiak BioSciences (CDAK) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement. The firm is developing therapeutics that harness exosomes - natural intercellular messengers - for diseases with unmet clinical needs.
Generation Bio 100S eries B Rubius Therapeutics 100S eries B Beam Therapeutics 87 Series A Compass Therapeutics 70 Series A Centrexion Therapeutics 67 Series D FogPharma 66 Series B Akero Therapeutics 65 Series A Nimbus Therapeutics 65 Series C Source: EvaluatePharma®, August 2018 Top Venture Capital Financings in Massachusetts, 2018 (Jan-July ... She is an inventor of their oral delivery technology, led the development of their lead product through all stages of development, including NDA submission. She was a key player in fundraising for the company including several private financing rounds and led a $70 million crossover financing and a successful IPO of over $100 million in 2015. More IPOs Will Be Replaced by Direct Listings. Why That’s a Good Thing for Investors. Bypassing the traditional IPO route may become more popular in 2020, and the stock exchanges are trying to help. www.barrons.com Codiak BioSciences, a venture-backed start-up in Cambridge, Mass, has appointed Ariel Jasie as Chief Business Officer, Linda Bain as CFO and Konstantin Konstantinov as Senior Vice President.